
Protagonist Therapeutics, Inc
Protagonist Therapeutics, Inc (PTGX)
WebsitePrice
Market cap
Next catalystHistorical PN-458 Phase 1 initiation forecast: Q4 2026; formulation unspecifiedPN-458 — planned oral-formulation Phase 1 · Trial initiationCompany source ↗
Cash
Chart & Events
Core Clinical
PreINDP2P3FilingApproved
PreINDP1P3FilingApproved
PreINDP2P3FilingApproved
PreINDP2P3FilingApproved
PreINDP2P3FilingApproved
PreINDP1P2P3FilingApproved
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Clinical
Upcoming clinical milestones
PreINDP1P3FilingApproved
PreINDP2P3FilingApproved
PreINDP2P3FilingApproved
PreINDP2P3FilingApproved
PreINDP2P3FilingApproved
PreINDP1P2P3FilingApproved
Other pipelines
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Partner / License out
History / paused
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved